Deoxycholic, hyaluronic acid injections may improve submental area, jawline definition
Click Here to Manage Email Alerts
Key takeaways:
- The combination treatment decreased fat in the submental area and increased volume in the jawline.
- Submental area angles decreased from baseline (76.6%) to final evaluation (60.85).
Dual modality with deoxycholic acid injections followed by hyaluronic acid filler may reduce submental fat and improve jawline contour, according to a study.
“An excess of submental fat can lead to an unappealing submental profile and poor jawline definition, thus affecting the overall appearance of the face,” Greg J. Goodman, MBBS, MD, FACD, of Monash University in Australia, and colleagues wrote. “As a result, individuals may seek aesthetic treatments for improving submental convexity and jawline contour.”
Such treatment options may include Juvéderm Voluma (VYC-20L, Allergen), a hyaluronic acid filler that restores volume midface and supports the chin, and Kybella (ATX-101, Allergen), a deoxycholic acid injection and cytolytic agent that causes lysis of adipocytes and is indicated for the improvement of moderate to severe convexity.
In this phase 4, prospective, open-label, multicenter study, the authors evaluated the safety and efficacy of ATX-101 followed by VYC-20L for the reduction of submental fullness and improving jawline definition.
Fifty-three participants (mean age, 48 years; 83% women; 96.2% white) received one to six ATX-101 treatments administered at least 8 weeks apart with a maximum volume of 10 mL per treatment. Eight weeks after the last ATX-101 treatment, a single VYC-20L treatment was administered. Additionally, there was an optional touch-up treatment after 14 days.
Compared with baseline, there was a mean volume increase of 0.9 cc and 1.2 cc for the left and right jawline, respectively, and a decrease of 5.7 cc for the submental area compared with baseline.
Stretch and expansion of the major strain increased by 3.6% from baseline, whereas the compression of the minor strain decreased by 9.1%. Submental area angles decreased 15.8° from baseline, indicating a more defined jawline. Collagen I and III expression significantly increased from baseline (P < .05), indicating neocollagenesis which may contribute to unchanged or improved skin laxity in the submental region.
Every participant reported at least one treatment-emergent adverse event related to ATX-101, and three patients reported a treatment-emergent adverse event associated with VYC-20L. The majority of these events (69.8%) were mild to moderate in severity. Two serious adverse events were deemed not related to treatment, and three patients discontinued treatment due to adverse events.
Collapse
Read more about
Click Here to Manage Email Alerts